Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.7
16.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZNTL stock under the Base Case scenario is 3.025 USD. Compared to the current market price of 3.945 USD, Zentalis Pharmaceuticals Inc is Overvalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zentalis Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZNTL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zentalis Pharmaceuticals Inc
Balance Sheet Decomposition
Zentalis Pharmaceuticals Inc
Current Assets | 439.6m |
Cash & Short-Term Investments | 426.4m |
Receivables | 3.3m |
Other Current Assets | 10m |
Non-Current Assets | 52.1m |
PP&E | 38.8m |
Intangibles | 3.7m |
Other Non-Current Assets | 9.5m |
Current Liabilities | 66.7m |
Accounts Payable | 20.4m |
Accrued Liabilities | 45.8m |
Other Current Liabilities | 425k |
Non-Current Liabilities | 42.4m |
Other Non-Current Liabilities | 42.4m |
Earnings Waterfall
Zentalis Pharmaceuticals Inc
Revenue
|
40.6m
USD
|
Operating Expenses
|
-261.1m
USD
|
Operating Income
|
-220.6m
USD
|
Other Expenses
|
25.9m
USD
|
Net Income
|
-194.7m
USD
|
Free Cash Flow Analysis
Zentalis Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
ZNTL Profitability Score
Profitability Due Diligence
Zentalis Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Zentalis Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
ZNTL Solvency Score
Solvency Due Diligence
Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ZNTL is 10.098 USD with a low forecast of 4.04 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for ZNTL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one ZNTL stock under the Base Case scenario is 3.025 USD.
Compared to the current market price of 3.945 USD, Zentalis Pharmaceuticals Inc is Overvalued by 23%.